Discovery and Characterization of an Endogenous CXCR4 Antagonist by O., Zirafi et al.
ArticleDiscovery and Characterization of an Endogenous
CXCR4 AntagonistGraphical AbstractHighlightsd The albumin fragment EPI-X4 is a highly specific endogenous
CXCR4 antagonist
d EPI-X4 blocks CXCL12-mediated CXCR4 signaling and
cellular migration
d EPI-X4 mobilizes hematopoietic cells and inhibits
inflammatory responses in vivo
d EPI-X4 is generated under acidic conditions that are a
hallmark of inflammationZirafi et al., 2015, Cell Reports 11, 737–747
May 5, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.03.061Authors
Onofrio Zirafi, Kyeong-Ae Kim, ...,
Frank Kirchhoff, Jan Mu¨nch
Correspondence
jan.muench@uni-ulm.de
In Brief
The CXCL12-CXCR4 axis is involved in
many physiological processes. Zirafi et al.
show that an endogenous fragment of
human serum albumin
(LVRYTKKVPQVSTPTL) efficiently
suppresses CXCR4 signaling and inhibits
infection by CXCR4-tropic HIV-1 strains.
Cell Reports
ArticleDiscovery and Characterization
of an Endogenous CXCR4 Antagonist
Onofrio Zirafi,1,18 Kyeong-Ae Kim,1,18 Ludger Sta¨ndker,1,2,8,18 Katharina B. Mohr,1 Daniel Sauter,1 Anke Heigele,1
Silvia F. Kluge,1 Eliza Wiercinska,3 Doreen Chudziak,3 Rudolf Richter,3,17 Barbara Moepps,4 Peter Gierschik,4 Virag Vas,5
Hartmut Geiger,5 Markus Lamla,6 Tanja Weil,6 Timo Burster,7 Andreas Zgraja,8 Francois Daubeuf,9 Nelly Frossard,9
Muriel Hachet-Haas,10 Fabian Heunisch,11 Christoph Reichetzeder,11 Jean-Luc Galzi,10 Javier Pe´rez-Castells,12
Angeles Canales-Mayordomo,13 Jesus Jime´nez-Barbero,13 Guillermo Gime´nez-Gallego,13 Marion Schneider,14
James Shorter,15 Amalio Telenti,16 Berthold Hocher,11 Wolf-Georg Forssmann,1,8,17 Halvard Bonig,3 Frank Kirchhoff,1,2
and Jan Mu¨nch1,2,*
1Institute of Molecular Virology, University of Ulm, 89081 Ulm, Germany
2Ulm Peptide Pharmaceuticals, University of Ulm, 89081 Ulm, Germany
3German Red Cross Blood Service Baden-Wu¨rttemberg-Hessen and Institute for Transfusion Medicine and Immunohaematology, Goethe
University, 60528 Frankfurt, Germany
4Institute of Pharmacology and Toxicology, University of Ulm, 89081 Ulm, Germany
5Department of Dermatology and Allergic Diseases, University of Ulm, 89081 Ulm, Germany
6Institute of Organic Chemistry III, University of Ulm, 89081 Ulm, Germany
7Department of Neurosurgery, University of Ulm, 89081 Ulm, Germany
8PHARIS Biotec GmbH, 30625 Hannover, Germany
9UMR7200, Therapeutic Innovation Lab, CNRS-University of Strasbourg, Faculty of Pharmacy, and LabEx Medalis, 67401 Illkirch, France
10UMR7242, Biotechnology and Cellular Signaling, School of Biotechnology of Strasbourg, 67412 Illkirch, France
11Institute of Nutritional Science, University of Potsdam, 14558 Nuthetal-Potsdam, Germany
12Department of Chemistry, University San Pablo-CEU, 280040 Madrid, Spain
13Department of Physico-Chemical Biology, Centro de Investigaciones Biolo´gicas, 28040 Madrid, Spain
14Experimental Anesthesiology Section, University Hospital Ulm, 89081 Ulm, Germany
15Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
16J. Craig Venter Institute, La Jolla, CA 92037, USA
17Department of Internal Medicine, Clinic of Immunology, Hannover Medical School, 30625 Hannover, Germany
18Co-first author
*Correspondence: jan.muench@uni-ulm.de
http://dx.doi.org/10.1016/j.celrep.2015.03.061
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
CXCL12-CXCR4 signaling controls multiple physio-
logical processes and its dysregulation is associ-
ated with cancers and inflammatory diseases. To
discover as-yet-unknown endogenous ligands of
CXCR4, we screened a blood-derived peptide li-
brary for inhibitors of CXCR4-tropic HIV-1 strains.
This approach identified a 16 amino acid fragment
of serum albumin as an effective and highly specific
CXCR4 antagonist. The endogenous peptide, ter-
med EPI-X4, is evolutionarily conserved and gener-
ated from the highly abundant albumin precursor by
pH-regulated proteases. EPI-X4 forms an unusual
lasso-like structure and antagonizes CXCL12-in-
duced tumor cell migration, mobilizes stem cells,
and suppresses inflammatory responses in mice.
Furthermore, the peptide is abundant in the urine
of patients with inflammatory kidney diseases and
may serve as a biomarker. Our results identify EPI-
X4 as a key regulator of CXCR4 signaling and intro-
duce proteolysis of an abundant precursor proteinas an alternative concept for chemokine receptor
regulation.INTRODUCTION
CXC chemokine receptor 4 (CXCR4) is a G protein-coupled re-
ceptor (GPCR) that is expressed on multiple cells, including
those of the hematopoietic and CNSs (Feng et al., 1996; Zou
et al., 1998). Activation of CXCR4 by its only known chemokine
ligand, stromal-cell-derived factor-1 (SDF-1 or CXCL12) (Bleul
et al., 1996; Oberlin et al., 1996), governs important physiological
processes, such as organogenesis, angiogenesis, migration of
immune cells, and renal function, as well as retention of hemato-
poietic stem cells (HSCs) in the bone marrow (Petit et al., 2002;
Nie et al., 2004; Chen et al., 2014). Deregulation of CXCR4/
CXCL12 signaling is associated with numerous pathological
conditions, including various types of cancers, chronic inflam-
matory diseases, cardiovascular diseases, and immunodefi-
ciencies (Gonzalo et al., 2000; Nanki et al., 2000; Mu¨ller et al.,
2001; Hernandez et al., 2003; Wen et al., 2012). Furthermore,
CXCR4 serves as a major coreceptor of HIV-1 entry (Bleul
et al., 1996; Oberlin et al., 1996). Thus, CXCR4 represents an
interesting drug target (Choi et al., 2012; Wen et al., 2012). SoCell Reports 11, 737–747, May 5, 2015 ª2015 The Authors 737
Figure 1. Identification of an Inhibitor of X4 HIV
(A) Anti-HIV activity of peptide fractions of a hemofiltrate (HF) library. +, no peptide added;, uninfected cells. Fractions 6–8 were used for further purification and
contained a 1,830 Da peptide with the indicated sequence. Values represent the mean ± SD of triplicate infections.
(B) EPI-X4 inhibits X4, but not CCR5 (R5), HIV. TZM-bl cells were infected with four X4 HIV NL4-3 constructs (left panel) or 18 CCR5-tropic derivatives thereof
(Papkalla et al., 2002) (right panel) in the presence of the indicated concentrations of EPI-X4. Shown are infection rates obtained 3 days post-infection. Values
represent the mean of triplicate infections (SDs are omitted for clarity).
(C) Synthetic EPI-X4 inhibits X4, but not R5, HIV-1. TZM-bl cells were infected with the indicated HIV-1 NL4-3 recombinants in the absence or presence of EPI-X4
(100 mg/ml), and infection rates were determined 3 days later. Values represent the mean ± SD of triplicate infections
(D) EPI-X4 blocks HIV-1 infection by interacting with the cell. X4 HIV-1 was pretreated with the peptide prior to infection or cells were treated with EPI-X4 and
subsequently infected with HIV-1 (cells). Values represent the mean of triplicate infections.
(E) EPI-X4 is not cytotoxic. Phytohemagglutinin/IL-2-stimulated peripheral blood mononuclear cells or TZM-bl cells were incubated with the indicated con-
centrations of EPI-X4. After 3 days, cell viability was measured by quantifying the cell-associated ATP levels. Values represent the mean ± SD of triplicate
cultures.
(F) Infection of TZM-bl cells with X4 and R5 HIV-1 in the presence of full-length HSA. Values represent the mean of triplicate infections.
See also Figure S1 and Tables S1 and S2.far, however, only a single antagonist (plerixafor, AMD3100) has
been approved for stem cell mobilization in patients who do not
respond to chemotherapy or granulocyte colony-stimulating
factor (G-CSF) (Devine et al., 2008).
To identify unknown endogenous CXCR4 ligands, we gener-
ated a peptide library derived from 10,000 l of hemofiltrate
(HF). This blood ultrafiltrate is obtained from dialysis centers
and contains essentially the entire circulating blood pepti-
dome with millions of compounds (Schulz-Knappe et al.,
1997; Mu¨nch et al., 2014). Previously, we used this resource
to discover an HIV-1 entry inhibitor that targets the viral
gp41 fusion peptide (Mu¨nch et al., 2007b), and demonstrated
that an optimized derivative thereof suppressed HIV-1 replica-
tion in humans (Forssmann et al., 2010). Furthermore, we
identified an agonist of CCR5 (Detheux et al., 2000; Mu¨nch
et al., 2002; Forssmann et al., 2010), the second main core-
ceptor of HIV-1 entry (Deng et al., 1996; Dragic et al., 1996).
Here, we screened an HF-derived peptide library for inhibitors
of CXCR4-tropic (X4) HIV-1 and identified an endogenous
antagonist of CXCR4 that is generated by limited proteolysis738 Cell Reports 11, 737–747, May 5, 2015 ª2015 The Authorsof serum albumin, the most abundant protein in human
plasma.
RESULTS
Isolation of an Endogenous Inhibitor of X4 HIV-1
The screening of 350 fractions of an HF-derived peptide library
identified three adjacent peptide fractions that blocked X4-
HIV-1 (Figure 1A). Further rounds of chromatographic separation
and X4-HIV-1 inhibition assays (Figure S1) yielded a peptide of
1,830 Da with the amino acid sequence LVRYTKKVPQVSTPTL,
which corresponds to residues 408–423 of human serum albu-
min (HSA) (Figure 1A). HSA is the most abundant protein in the
blood, with reference concentrations between 34 and 54 g/l,
and is also abundant in the extravascular space (Peters, 1996).
The isolated peptide was previously detected by mass spec-
trometry in HF and the urine of patients with graft-versus-host
and kidney disease (Kaiser et al., 2004; Chalmers et al., 2005;
Wittke et al., 2005; Aristoteli et al., 2007), but its biological func-
tion remained unknown.
Figure 2. EPI-X4 Antagonizes CXCR4 and Suppresses CXCL12-Mediated Cellular Migration
(A) EPI-X4 and the synthetic control CXCR4 antagonist T134 inhibit binding of CXCL12 to CXCR4 in a dose-dependent manner. Each data point represents the
mean ± SD of three experiments.
(B) EPI-X4 antagonizes CXCL12-mediated Ca2+ mobilization. HEK293 CXCR4 cells were treated with CXCL12 in the absence or presence of EPI-X4, and Ca2+
mobilization was monitored. Values shown are the mean Ca2+ peak responses from triplicate experiments relative to cells treated only with chemokine (100%).
(C) EPI-X4 blocks CXCL12-directed transwell migration of Jurkat T cells. Values shown were derived from one representative experiment performed in triplicate.
(D) EPI-X4 blocks CXCL12-induced migration of human CD34+ stem cells. Values shown were derived from one experiment performed in triplicate.
(E) The peptide blocks invasion of prostate cancer cells. Values shown were derived from one experiment performed in duplicate.
See also Figure S2.The synthetic peptide inhibited X4-HIV-1 infection with a
mean 50% inhibitory concentration (IC50) of 15.8 mg/ml (corre-
sponding to 8.6 mM) (Figure 1B; Table S1), but had no effect on
CCR5- (R5) tropic HIV-1 strains (Figures 1B and 1C). Treatment
of target cells, but not of virions, prevented HIV-1 infection (Fig-
ure 1D), suggesting that the peptide, named EPI-X4 (endoge-
nous peptide inhibitor of CXCR4), targets the CXCR4 coreceptor
of HIV-1 entry. EPI-X4 is not cytotoxic (Figure 1E; Table S2) and
its albumin precursor exhibited no antiviral effect (Figure 1F).
Thus, a naturally occurring fragment of the most abundant pro-
tein in human plasma specifically inhibits X4 HIV-1 infection.
EPI-X4 Is a Natural CXCR4 Antagonist
We next determined whether EPI-X4 interacts directly with
CXCR4. EPI-X4 competed for CXCL12 binding to CXCR4 with
an IC50 of 8.6 ± 3.1 mM, corresponding to a dissociation constant
(Ki value) of 3 ± 1 mM (Figure 2A). Thus, active concentrations of
this peptide can be generated by proteolytic cleavage of1% of
its albumin precursor. The peptide also interfered with the bind-
ing of the monoclonal antibody 12G5, which interacts with the
second extracellular loop of CXCR4, but had no effect on 1D9,
which targets the N terminus (Figure S2A). EPI-X4 did not induce
Ca2+ mobilization (Figure S2B) and has thus no CXCR4 agonistic
activity. However, EPI-X4 inhibited CXCL12-induced Ca2+ mobi-
lization (Figures 2B and S2B) and receptor internalization (Fig-
ures S2C and S2D). These effects were highly specific since
EPI-X4 did not affect ligand-induced signaling via any other
GPCR investigated (Figures S2B and S2E). Furthermore, EPI-
X4 did not interfere with CXCL12-induced internalization of
CXCR7 (Figure S2F), the alternative receptor for CXCL12 (Burns
et al., 2006), and suppressed basal CXCR4 signaling (Fig-
ure S2G). Next, we examined whether EPI-X4 affects cellular
migration along a CXCL12 gradient. We found that EPI-X4 in-
hibits CXCL12-induced migration of leukemia cells (Figure 2C)
and human CD34+ hematopoietic cells (Figure 2D), as well as
prostate tumor cell invasion (Figure 2E). Thus, EPI-X4 is anendogenous antagonist and inverse agonist of CXCR4 that ex-
erts anti-invasive and anti-metastatic effects.
EPI-X4 Modulates CXCR4 Signaling In Vivo
Expression of CXCL12 by bone marrow stromal cells provides a
retention signal for CXCR4-expressing HSCs and neutrophils in
the bone marrow. In agreement with the antagonistic activity of
EPI-X4 described above, a single intraperitoneal injection of
this peptide into mice resulted in marked mobilization of HSCs
(Figure 3A) and neutrophils (Figure 3B) into the periphery.
Notably, the mobilized cells included transplantable cells, as
they engrafted lethally irradiated hosts (Figure 3C). Given that
CXCR4 plays a key role in inflammation, we also examined
whether EPI-X4 exerts anti-inflammatory effects in a mouse
model of acute allergic airway hypereosinophilia (Reber et al.,
2012). Administration of EPI-X4 prior to allergen (ovalbumin
[OVA]) challenge reducedCXCR4-dependent infiltration of eosin-
ophils, neutrophils, and lymphocytes into the airways, whereas a
derivative lacking the N-terminal L (Table S1) was inactive (Fig-
ure 3D). Thus, EPI-X4 mobilizes HSCs and exerts anti-inflamma-
tory effects in vivo.
EPI-X4 Is Evolutionarily Conserved
A physiologically relevant CXCR4 antagonist should be evolu-
tionarily conserved. Indeed, alignment of albumin sequences
from different mammalian species revealed variations at only
three amino acid positions of EPI-X4: L1I/A, K6R/Q, and V8A/L
(Figure 4A). Quantitative analyses confirmed that the conser-
vation score of the region corresponding to EPI-X4 and its
flanking residues (that may allow its proteolytic generation) is
significantly greater (0.98) than that of the remainder of the albu-
min molecule (0.87; p = 0.006; Figures 4B and 4C). Importantly,
substitution of the N-terminal L by I, which was observed in
several species (Figure 4A), increased the activity of human
EPI-X4 (Table S1). Notably, both human- and murine-derived
EPI-X4 efficiently suppressed CXCL12-induced migration ofCell Reports 11, 737–747, May 5, 2015 ª2015 The Authors 739
Figure 3. EPI-X4 Mobilizes Stem Cells and Inhibits Inflammation In Vivo
(A and B) Intraperitoneal administration of EPI-X4 into mice results in mobilization of clonogenic cells (CFU-C) (A) and neutrophils (B) in peripheral blood (PB).
Values are mean values derived from n = 3 mice ± SEM.
(C) EPI-X4 mobilizes mouse stem cells. Multi-lineage chimerism of a donor-specific cell-surface marker (Ly5.2) in mice that were competitively transplanted with
equal volumes of blood derived from mice given either EPI-X4 or saline. Values are mean values derived 8 or 12 weeks (w) after engraftment from n = 3 mice per
group ± SEM.
(D) EPI-X4 inhibits inflammatory cell infiltration in a mouse model of allergic hypereosinophilia. Data are presented as means ± SEM from six mice per group.
*p < 0.05, ***p < 0.001). L EPI-X4 lacks the N-terminal leucine.
See also Table S1.mouse cells (Figure 4D), suggesting that this endogenousCXCR4
antagonist is functionally conserved from mice to humans.
Structure and Optimization of EPI-X4
To better understand the mechanism underlying EPI-X4 function,
we usedNMR to solve its 3D structure (Figure 5A; Table S3). Inter-
actions among L1, Y4, and P9 cause the backbone of the L1–P9
stretch to adopt a ring-like structure with a ‘‘tail’’ formed by resi-
dues V11–L16 (Figure 5B). The ring displays one highly positively
charged and one strongly hydrophobic surface (Figure 5C).
Computational modeling with the published CXCR4 structure
(Wu et al., 2010) suggests that the positively charged face of the
ring of EPI-X4 interacts with the negatively charged extracellular
face of CXCR4 similarly to CXCL12 and the V3 loop of the HIV-1
gp120 exterior envelope glycoprotein (Figure S3).
Indeed, mutational analyses demonstrated that truncations of
the C-terminal tail were tolerated (Figure 6A; Table S1), whereas
N-terminal truncations that eliminated the ring structure resulted
in a loss of activity (Figure 6B). Furthermore, substitutions of L1I
(Figure 6C) and Y4W or T5S (Figure 6D) increased the antiviral
activity, and combinations of these mutations (Figure 6E),
including dimerization (Figure 6F), resulted in EPI-X4 derivatives
with IC50 values in the nanomolar range (Table S1). The antiviral
activity of optimized EPI-X4 derivatives correlated with their po-
tency in inhibiting T cell migration (Figure S4A). The optimized
dimeric WSC02x2 derivative also displayed strongly increased
serum stability (Figure S4B), and suppressed CXCL12-induced
actin polymerization in T cells (Figure S4C) and HSC migration
(Figure S4D) more effectively than the parental peptide. Thus,
these analyses allowed the generation of EPI-X4 derivatives
with substantially increased stability and potency.
Half-Life of EPI-X4
For fast and effective regulation of CXCR4, the activity of EPI-X4
should be tightly regulated. In agreement with this requirement,
the half-life of EPI-X4 spiked into plasma from healthy human
individuals was only 17 min (Figure 7A), as determined by an
EPI-X4-specific sandwich ELISA (Mohr et al., 2015). Degradation740 Cell Reports 11, 737–747, May 5, 2015 ª2015 The Authorsand functional inactivation in plasma were blocked by L-leucine-
thiol (LT), an inhibitor of leucyl aminopeptidases (LAPs; Fig-
ure 7B), a group of cell-maintenance enzymes that play critical
roles in the turnover of bioactive peptides and immune function
(Matsui et al., 2006). These results underline the critical role of
the N-terminal L-residue in the antagonistic activity of EPI-X4.
Generation of EPI-X4 from Albumin
EPI-X4 is accessible at the surface of albumin and flanked by
putative protease cleavage sites (Figure S5A). We found that
cathepsins D and E efficiently generated EPI-X4 from albumin
under acidic conditions (Figure 7C). These aspartic proteases
are major components of the endo- and lysosomal protein
degradation pathway of virtually all cells (Zaidi and Kalbacher,
2008; Sun et al., 2013) and are released by exocytosis from im-
mune cells during inflammatory processes (Yamamoto et al.,
2012; Appelqvist et al., 2013). Indeed, immature dendritic cells
and neutrophils supplemented with albumin produced EPI-X4
(Figure S6). Cathepsin D also circulates in an inactive form in hu-
man blood and is activated under acidic pH conditions (Tandon
et al., 1990). Remarkably, we found that acidification of human
plasma, which usually does not contain detectable amounts of
EPI-X4 (Mohr et al., 2015), resulted in the effective de novo gen-
eration of biologically active concentrations of the CXCR4 antag-
onist (Figure 7D), and this process was blocked by pepstatin A,
an inhibitor of aspartic proteases (Figure 7E). In agreement with a
conserved regulatory role in CXCR4 signaling, EPI-X4 was also
detectable in acidified sera from rhesus macaques (Figure S5B)
and mice (Figure S5C). Notably, we detected higher levels of
EPI-X4 in acidified sera of HIV-infected individuals with rapid dis-
ease progression (36.7 ± 9.0 mg/ml, n = 37) or chronic disease
(27.9 ± 8.5 mg/ml, n = 56) than in sera obtained from elite control-
lers (6.3 ± 6.2 mg/ml, n = 9; Figure 7F). Thus, sera from patients
with high levels of inflammation have an increased potential to
generate EPI-X4. Altogether, these results suggest that EPI-X4
is effectively generated by acidic proteases present at sites of
infection or inflammation, but is rapidly inactivated by serum
LAP in neutral, non-inflammatory environments.
Figure 4. Structural and Functional Conservation of EPI-X4
(A) Sequence alignment of albumin proteins of the indicated species.
(B) The EPI-X4 sequence (residues 408–423) and flanking protease recognition sites (407–424) are more conserved than the remainder of the protein. Protein
sequences of 21 mammalian species were aligned and residue conservation was determined using the Scorecons Server.
(C) Higher conservation of EPI-X4 and its flanking protease recognition sites (407–424) compared with the remaining sites in mammalian albumins.
(D) Murine EPI-X4 suppresses CXCL12-induced migration of mouse pro-B cells. Shown are mean values from triplicate experiments ± SD.
See also Table S1.Urinary EPI-X4 Is a Marker for Chronic Kidney Disease
To determine whether EPI-X4 is induced under inflammatory
conditions, we measured its urinary levels in patients with
renal failure and in healthy controls (without prior acidification
of the urine samples). High levels of EPI-X4 (1.73 ± 0.87 mg/ml,
n = 12) were detected in the urine of patients with macroalbu-
minuria. In contrast, the levels were low in individuals with
microalbuminuria (0.22 ± 0.10 mg/ml, n = 39) and essentially
absent in those with no albuminuria (0.024 ± 0.004 mg/ml,n = 277; Figure 7G). Furthermore, the urinary levels of EPI-
X4 were inversely correlated with the glomerular filtration
rate (GFR) in these patients (r = 0.131, p = 0.026). Notably,
we never observed that EPI-X4 was produced after urination,
and its concentrations remained stable in urine over several
days (Mohr et al., 2015). Thus, EPI-X4 is likely generated by
the kidneys in vivo and its urinary levels may represent a prog-
nostic marker for renal inflammation and chronic kidney
disease.Cell Reports 11, 737–747, May 5, 2015 ª2015 The Authors 741
Figure 5. EPI-X4 Structure and Binding
Model of CXCL12
(A) Superposition of 20 EPI-X4 conformers with the
lowest final CYANA target function values.
(B) Backbone of the mean 3D structure of EPI-X4.
(C) Electrostatic potential of the surface of EPI-X4
according to the calibration bar. The images on the
right were obtained after a 170 counterclockwise
turn over the y axis of those on the left.
See also Figure S3 and Table S3.DISCUSSION
In the present study, we identified EPI-X4 as an evolutionarily
conserved endogenous antagonist of CXCR4 that may play
important roles in physiological processes and diseases. EPI-
X4 is an endogenous antagonist of a chemokine receptor that
is generated from a highly abundant protein with unrelated func-
tion. The precursor, serum albumin, is ubiquitously present in
intra- and extravascular compartments of the entire body with
reference concentrations between 34 and 54 mg/ml (Peters,
1996). The EPI-X4-generating proteases are also available any-
where in human plasma. Thus, the ‘‘prerequisites’’ for rapid
generation of the CXCR4 antagonist are essentially provided
everywhere in the human body.
Production of EPI-X4 is likely induced by local extracellular
acidification, which represents a hallmark of inflammatory tis-
sues (Mogi et al., 2009; Dong et al., 2013; Okajima, 2013) and
is emerging as a key regulatory concept for innate immunity (Ra-
jama¨ki et al., 2013). Acidification results in the activation of as-
partic proteases, such as cathepsins D and E, that may be
secreted by lysosomal exocytosis during immune responses
(Rodrı´guez et al., 1997; Stinchcombe et al., 2000) or via special-
ized secretory granules of immune cells (Levy et al., 1989; Burns
et al., 2006; Yamamoto et al., 2012). Thus, EPI-X4 most likely is
specifically generated at sites of infection and inflammation, and
may help to trap immune cells at their places of action by pre-
venting CXCR4-dependent migration. In addition, EPI-X4 may
also be generated intracellular by lysosomal degradation of albu-
min (Benes et al., 2008) and subsequent release into the extra-
cellular space after apoptosis or pyroptosis. Acidic pH values
and high levels of cathepsin D are also characteristic of malig-
nant tumors (Liaudet-Coopman et al., 2006; Benes et al., 2008;
Estrella et al., 2013; Kato et al., 2013). Since EPI-X4 suppresses
themigration of tumor cells, it will be of high interest to determine
whether this endogenous CXCR4 antagonist may affect cancer
development and tumor metastasis in vivo.
Our results support previous hypotheses that urinary EPI-X4
might serve as an early marker for renal damage, as the appear-
ance of this peptide seems to be affected by initial changes in
proteolytic activity associated with inflammatory processes at
the onset of renal disease (Chalmers et al., 2005; Wittke et al.,
2005). The CXCR4/CXCL12 signaling pair preserves microvas-
cular integrity and renal function in patients with chronic kidney
disease (Chen et al., 2014), and elevated levels of CXCL12 pre-
dict incident of myocardial infarction and death in these patients
(Mehta et al., 2014). Thus, increased endogenous levels of EPI-
X4 may represent a specific response against overshooting
CXCR4 signaling. Moreover, these observations suggest that742 Cell Reports 11, 737–747, May 5, 2015 ª2015 The AuthorsEPI-X4 or its improved derivatives have therapeutic potential in
chronic kidney disease and associated disorders.
EPI-X4 was initially identified as an inhibitor of X4 HIV-1. It is
tempting to speculate that the emergence of X4 HIV-1 strains
during the chronic phase of infection (Connor et al., 1997) might
correlate with declining concentrations of EPI-X4. However, EPI-
X4 could not be detected in non-acidified plasma samples
derived from HIV-1-infected individuals with late-stage disease,
arguing against an essential role of EPI-X4 in the coreceptor
switch. Whether or not occupancy of CXCR4 by EPI-X4 repre-
sents the long-sought ‘‘gate-keeping’’ mechanism that restricts
sexual or perinatal transmission of X4 HIV-1 is being addressed
in ongoing studies.
The finding that EPI-X4 also reduces the basal signaling activ-
ity of CXCR4 and thus acts as an inverse agonist may have
important implications because it suggests that CXCR4 activity
is not solely dependent on CXCL12. CXCR4 is of significant inter-
est as a drug target (Peled et al., 2012; Cojoc et al., 2013), and
EPI-X4 has interesting properties for clinical development
because it mobilizes stem cells and prevents inflammatory cell
infiltration in vivo. Moreover, it is not immunogenic or cytotoxic,
whereas plerixafor, the only approved CXCR4 antagonist (De-
vine et al., 2008), affects mitochondria function (Table S2).
Furthermore, EPI-X4 is functionally distinct from plerixafor
because it does not bind to CXCR7 and also acts as an inverse
agonist of CXCR4. Many clinically used GPCR antagonists
display inverse agonist activity (Kenakin, 2004). Thus, EPI-X4
and its derivatives may be useful for the treatment of diseases
associated with excessive activity of CXCR4, such as chronic in-
flammatory disorders and WHIM syndrome, a congenital immu-
nodeficiency associated with increased susceptibility to human
papilloma virus infection (Hernandez et al., 2003).
Our identification of an endogenous antagonist of CXCR4
signaling opens up exciting possibilities for future research.
The proteolytic generation of a bioactive peptide from an abun-
dant precursor protein represents a novel concept for the regu-
lation of GPCRs, which are the largest andmost diverse group of
membrane receptors in eukaryotes and targets of almost half of
all modern drugs (Lappano andMaggiolini, 2011). Our data show
that this regulation of CXCR4 activity is conserved from mice to
humans, and it will be interesting to determine whether other
GPCRs are regulated by similar means.EXPERIMENTAL PROCEDURES
Generation and Screening of HF Libraries
Fractions of an HF-derived peptide library (Schulz-Knappe et al., 1997) were
tested for their ability to block X4 HIV-1 NL4-3 infection in P4-CCR5 cells
Figure 6. Antiviral Activity of EPI-X4 Derivatives against X4 HIV
(A–F) EPI-X4 (depicted as 408–423) and derivatives thereof were added to TZM-bl cells and infected with HIV-1 NL4-3. Infection rates were determined 3 days
later by quantification of b-galactosidase activities. Shown aremean values from triplicate infections (bars indicating the SDs are omitted for clarity). The individual
panels show the antiviral activity of C-terminal truncations of EPI-X4 (A), N-terminal truncations of EPI-X4 (B), 408–419 derivatives with substitutions at L1 (C),
408–419 L1I derivatives (D), 408–419 L1I derivatives carrying cysteines (E), and the respective dimeric mutants (F).
See also Figure S4 and Table S1.(Mu¨nch et al., 2007b). The cells were grown in DMEM supplemented with 10%
fetal calf serum (FCS) and 1 mg/ml puromycin (GIBCO BRL). Cells were
seeded in flat-bottomed 96-well dishes, cultured overnight, and incubated
with fractions for 2 hr before they were infected with virus containing 20 ng
of p24 antigen in a total volume of 100 ml of medium. Three days after infection,
the cells were lysed and infection rates were determined using the one-step
Tropix Gal-Screen Kit as recommended by the manufacturer. Peptides were
synthesized and the effects on HIV-1 infection in TZM-bl cells were determined
as previously described (Mu¨nch et al., 2007a, 2007b). Infection rates were
determined after 3 days using the one-step Tropix Gal-Screen Kit.
Real-Time Fluorescence Monitoring of Ligand-Receptor
Interactions
The human chemokines CXCL12 and CXCL12-TexasRed were kindly pro-
vided by Dr. F. Baleux (Institut Pasteur, Paris, France). The synthesized T134
peptide (Tamamura et al., 1998), a small analog of T22 (a peptide derived
from the polyphemusin II), was purchased from Genecust. Experiments
were performed using HEK293 cells stably expressing EGFP-hCXCR4, sus-
pended in HEPES-BSA buffer. Time-based recordings of the fluorescence
emitted at 510 nm (excitation at 470 nm) were performed at 21C with a spec-
trofluorometer and sampled every 0.3 s. Fluorescence binding measurements
were initiated at 30 s by adding 100 nM of CXCL12-TR. For competition exper-iments, EGFP-CXCR4-expressing cells were preincubated for 10 min in the
absence or presence of various concentrations of unlabeled T134 or EPI-X4.
Subsequently, CXCL12-TR (100 nM) was added, and fluorescence was re-
corded until equilibrium was reached (300 s). Data were analyzed using Kalei-
daGraph 3.08 software (Synergy Software).
Intracellular Ca2+ Release Measurement
Measurements of intracellular Ca2+ release were carried out as previously
described (Tamamura et al., 1998; Hachet-Haas et al., 2008) using indo-1 ace-
toxymethyl ester as the calcium probe. HEK293 cells expressing CXCR4,
CCR5, or CXCR1 were preincubated for 30 min with 100 mM of EPI-X4 or
buffer. Calcium release was induced by addition of their natural ligands
(CXCL12, 10 nM; CCL5, 50 nM; and CXCL8, 50 nM). Cellular responses
were recorded at 37C in a 1 ml stirring cuvette with excitation set at
355 nm and emission set at 405 and 475 nm using a spectrofluorometer.
Data were analyzed using KaleidaGraph 3.08 software (Synergy Software).
The human chemokines CCL5, CXCL8, and CXCL11 were purchased from
Clinisciences SAS.
Effect of EPI-X4 and Derivatives on Cell Migration
Migration of Jurkat cells was analyzed using 6.5-mm-diameter chambers with
5-mm-pore filters (transwell, 24-well cell culture; Costar). Jurkat cells (23 105)Cell Reports 11, 737–747, May 5, 2015 ª2015 The Authors 743
Figure 7. Degradation and Generation of EPI-X4
(A) Half-life of EPI-X4 in human plasma.
(B) EPI-X4 is degraded by recombinant or plasma leucyl aminopeptidases (LAPs). LT, L-leucinethiol (LAP inhibitor).
(C) pH-dependent generation of EPI-X4 from purified albumin by cathepsins D and E, but not neutrophil elastase or cathepsin G.
(D) Generation of EPI-X4 in acidified human plasma.
(E) The aspartyl protease inhibitor pepstatin A blocks EPI-X4 production in acidified plasma. Values shown in (A)–(E) were determined by an EPI-X4-specific
sandwich ELISA and represent single data points from one representative experiment of two performed.
(F) EPI-X4 levels in acidified plasma of treatment-naive HIV-1-infected individuals.
(G) EPI-X4 concentrations in urine of patients with microalbuminuria, macroalbuminuria, or no albuminuria.
See also Figures S5 and S6.were suspended in 200 ml of OpTmizer T Cell Expansion serum-free medium
(SFM) (Life Technologies) and the cell suspensions were added to the upper
chamber. Then, various concentrations of EPI-X4 or its derivatives in 600 ml
T Cell Expansion SFM were added to the upper and lower chambers, and
10 nMof CXCL12 (R&DSystem)was added to the lower chamber. The cell-cul-
ture chambers were incubated for 150 min in a cell-culture incubator at 37C.
After incubation, chambers were removed, 100 ml of supernatants was taken,
and cells that had migrated into the lower compartment were either counted
directly using a hemocytometer or analyzed using the CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega). All values represent mean numbers of
migrated cells relative to CXCL12-only treated cells from a triplicate experi-
ment ± SD.
Migration of human CD34+ cells was performed using frozen CD34+
cells from G-CSF-mobilized healthy volunteer donor apheresis products
from the Institute for Transfusion Medicine (University of Ulm) and the
Institute for Clinical Transfusion Medicine and Immunogenetics Ulm. Cells
were maintained in CellGro SCGM medium (CellGenix) supplemented with
10% FCS, 100 ng/ml rhSCF, 20 ng/ml rhIL-3, and 25 ng/ml rhIL-6. Frozen
cells were carefully thawed in 1/10 diluted 10% ACD-A buffer in PBS, and
1 3 105/200 ml cells were placed into the upper chamber of transwell
plates. Various concentrations of EPI-X4 were then added to the upper
and lower chambers, and 10 nM CXCL12 was placed in the bottom
well. After 3 hr, chemotaxis was measured using the CellTiter-Glo Lumi-
nescent Cell Viability Assay as described above. Values shown represent
the mean percentage of migrated cells from one experiment performed in
duplicate.744 Cell Reports 11, 737–747, May 5, 2015 ª2015 The AuthorsCancer Cell Invasion
Invasion of cancer cells was assayed using a BioCoat Matrigel invasion
chamber (BD) as recommended by the manufacturer. In brief, 5 3 104
DU145 cells (ATCC) were suspended in 300 ml of serum-free RPMI (GIBCO)
containing 0.1% BSA (KPL) and then added to the upper chamber. Then,
700 ml serum-free medium with or without 100 nM CXCL12 and the indicated
concentrations of EPI-X4 were added to each lower chamber. The chambers
were incubated for 24 hr at 37C in a humid atmosphere of 5% CO2/95% air.
The non-invading cells were removed from the upper surface of the mem-
brane by scrubbing. Invaded cells toward the bottom of the membrane
were quantified using the CellTiter-Glo Luminescent Cell Viability Assay kit
as described above. Values shown are relative to those obtained for
CXCL12 alone.
Progenitor Cell Mobilization in Mice
C57Bl/6J mice (Janvier) were housed in the conventional vivarium of the
Goethe University Medical Center, Frankfurt, with food and water provided
ad libitum. Mice received intraperitoneal (i.p.) injections of 200 ml of normal sa-
line or normal saline containing 10 mg/ml EPI-X4. At the indicated times after
injection, blood was drawn from the cheek pouch after careful skin disinfec-
tion. After hypotonic lysis of erythrocytes, leukocytes were incubated in dupli-
cate in cytokine-replete, commercially available semisolid medium (3434,
Stem Cell Technologies) under standard conditions. Colony-forming units in
culture (CFU-C) were scored on day 7 as previously described (Bonig et al.,
2006). CFU-C scores were normalized to the blood volume incubated and
are expressed as CFU-C/ml.
Neutrophil Mobilization and Transplantation of Mobilized Cells
C57BL/6 animals were injected with EPI-X4 (2 mg i.p. in saline) or control sa-
line. Peripheral blood cells (with the Ly5.2 [CD45.2] cell-surface phenotype)
were individually harvested at 1 hr post-injection, counted (the percentage
of neutrophils in peripheral blood was determined using a differential blood
cell counter [Hemavet; Drew Scientific]), combined, and competitively trans-
planted (660 ml blood equivalent) alongside 43 105 C57BL/6 CD45.1 BM cells
into C57BL/6 Cd45.1 recipients as previously described (Ryan et al., 2010).
Recipient animals were subsequently analyzed for long-term multi-lineage
chimerism in peripheral blood by flow cytometry.
Acute Allergic Airway Hypereosinophilia Mouse Model
On days 0, 1, and 2, mice were sensitized by i.p. injections of 50 mg OVA
(A5503, Sigma-Aldrich) adsorbed on 2 mg of aluminum hydroxide (23918-6,
Sigma-Aldrich) in saline. Mice were challenged by intranasal (i.n.) instillation
of 10 mg OVA in 25 ml saline (12.5 ml/nostril) or saline alone for control mice
on days 5, 6, and 7 under anesthesia (50 mg/kg ketamine and 3.3 mg/kg xyla-
zine, i.p.). EPI-X4 or albumin fragment 409–423 in saline were administered i.p.
(16 mmol/kg) 2 hr before each OVA challenge. Bronchoalveolar lavage (BAL)
and differential cell counts were performed 24 hr after the last OVA challenge
as previously described (Reber et al., 2012).
Cell Migration of Murine Pro-B Cells
Migration of murine BA/F3 pro-B cells was determined in a transwell assay as
described in the Supplemental Experimental Procedures.
Degradation of EPI-X4 by LAP
In vitro degradation of EPI-X4 was performed by incubating 5 mg/ml EPI-X4 in
undiluted fresh human plasma in the presence or absence of 0.05 U of LAP
(L5006, Sigma-Aldrich) and 300 mM of LT (L8397, Sigma-Aldrich). Samples
were incubated at 37C for 1 hr and analyzed in an EPI-X4-specific sandwich
ELISA.
Half-Life of EPI-X4 in Human Plasma
Fresh human plasma was spiked with 1 mg/ml EPI-X4 and incubated at 37C
and 5% CO2. At the indicated times, aliquots were taken and analyzed by
an EPI-X4-specific sandwich ELISA.
HSA Structure
The 3D HSA structure was downloaded from the RCSB Protein Data Bank
(PDB ID: 1H9Z), and pictures were generated using PyMOL software (DeLano
Scientific LLC).
Proteolytic Digestion of HSA with Cathepsins
In vitro digestion of HSA was performed by incubating 400 mg/ml of HSA
(126654, Calbiochem) in the presence or absence of 10 mg/ml of cathepsin
D (C8696, Sigma-Aldrich) and cathepsin E (1294-AS-010; R&D Systems) or
a buffer control in 50 ml of 0.2 M citrate buffer at the indicated pH. Samples
were incubated at 37C for 4 hr and then placed on ice to stop the digestion.
Samples were analyzed in an EPI-X4-specific sandwich ELISA.
De Novo Generation of EPI-X4 in Acidified Plasma
Fresh human plasma or PBS was acidified to pH 4 with 1 M of HCl. At the indi-
cated time points, aliquots were taken and immediately stored at 80C. The
effect of a protease inhibitor (PI) cocktail (P8340, Sigma-Aldrich) on EPI-X4
generation was investigated by mixing 95% of acidified human plasma with
5% (v/v) of the protease inhibitor cocktail 1%, 5% (v/v) of DMSO (solvent),
or 5% (v/v) of PBS. The effect of individual protease inhibitors was analyzed
the same way. The final concentrations of individual PIs were 100 mM AEBSF
(A8456, Sigma-Aldrich), 100 nM aprotinin (A1153, Sigma-Aldrich), 1 mMbesta-
tin (B8385, Sigma), 10 mM E64 (E3132, Sigma-Aldrich), 10 mM leupeptin
(L2884, Sigma-Aldrich), and 1 mM pepstatin A (P5318, Sigma-Aldrich). EPI-
X4 concentrations were determined by EPI-X4-specific sandwich ELISA.
Detection of EPI-X4 in Sera from HIV-Infected Individuals
Plasma and serum from 102 HIV-infected individuals representing the full
spectrum of viral load and disease progression were obtained from the SwissHIV Cohort Study. Samples were collected while the individuals were treat-
ment naive. See the Supplemental Experimental Procedures for details.
Detection of Urinary EPI-X4 and Correlation with the Severity of
Chronic Kidney Disease
A total of 289 baseline urine samples from the Berlin Radio Contrast Media
Study were analyzed (Heunisch et al., 2014). Baseline urine analyzed in this
study was obtained before contrast media exposure. Patients had chronic kid-
ney disease (stages 1–4) and clinical signs of coronary artery disease. Patients
were classified according to albumin excretion (urine albumin concentrations:
0–29.9 mg/l = normal, 30–299.9 mg/l = microalbuminuria; 300–6,000 mg/l =
macroalbuminuria) and impairment of GFR (stage 1: 90–120 ml/min; stage 2
60–79.9 ml/min; stage 3: 30–59.9 ml/min; stage 4: 15–29.9 ml/min). Statistical
analysis was done with SPSS 20 (IBM SPSS Statistics; IBM), and p < 0.05 was
considered statistically significant.
Statistics
Statistical analysis of the results was done using GraphPad Prism 4.0
software.
Study Approval
All mouse experiments were performed in accordance with institutional and
national guidelines and regulations, and were approved by the local commit-
tees (permit AL/11/40/12/12 from the Comite´ Re´gional d’Ethique en Matie`re
d’Expe´rimentation Animale de Strasbourg [N.F.] and permit F27/19 from Re-
gierungspra¨sidium Darmstadt and the IACUC of Goethe University [H.B.]).
All patient samples were collected and analyzed with the patient’s written
informed consent prior to inclusion in the study.
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